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A B S T R A C T
Objective: To evaluate the efficacy of a dissolvable strip containing 15% w/w calcium sodium phosphosilicate
(CSPS) (Novamin®) in providing rapid relief from dentine hypersensitivity (DH).
Methods: In this examiner-blind, proof-of-principle study, 120 healthy adults with DH were randomized 1:1 to
the Test strip, professionally applied to facial surfaces of two selected teeth, or to No treatment. Sensitivity was
assessed at baseline and 10 min, 2 h and 4 h post-application in response to evaporative (air) and tactile stimuli
(measured by Schiff sensitivity scale/a numeric rating scale and tactile threshold, respectively). Change from
baseline was analyzed by ANCOVA.
Results: At 10 min post-application, mean Schiff score change from baseline (primary endpoint) was statistically
significant with the Test strip (−0.46; 95% confidence intervals [CI]: −0.563, −0.356; p < 0.0001) but not
with No treatment (−0.02; 95% CI: −0.119, 0.088; p = 0.7664). The between-treatment group difference fa-
vored the Test strip (difference:−0.44; 95% CI:−0.591,−0.297; p < 0.0001). Similar improvements with the
Test strip were reported for all other evaporative (air) and tactile sensitivity endpoints (p < 0.0001 vs no-
treatment) at all timepoints (10 min, 2 h, 4 h). Test strips were considered by most staff and participants
slightly/moderately easy to apply (98%). Many participants rated the overall usage experience as “like mod-
erately” (40%) or “like extremely” (20%). There were no treatment-related adverse events.
Conclusion: This new CSPS-based technology may provide a novel treatment option for rapid relief from DH
(Clinicaltrials.gov NCT02937623).
Clinical significance: A dissolvable strip containing 15% w/w calcium sodium phosphosilicate (CSPS) demon-
strated significantly greater dentine hypersensitivity reductions following a single application compared with no
treatment. Strips were well-liked by participants and generally well tolerated. A strip containing CSPS, which
dissolves within 10 min, may provide rapid relief from dentine hypersensitivity.
Introduction
Dentine hypersensitivity (DH) is characterized by a transient and
sharp burst of pain arising from exposed cervical dentine in response to
external thermal, evaporative, tactile, osmotic or chemical stimuli, not
attributed to other forms of dental defect or disease [1]. Global pre-
valence of DH is increasing, partly due to people retaining their natural
dentition longer and the rise in erosive tooth wear [2]. A cross-sectional
study of general dental practice adults in the United States (US) re-
ported a DH prevalence of 12.3% [3], while a European study showed
that 42.0% of young adults reported some degree of pain on cold air
tooth stimulation [4].
The hydrodynamic theory of DH proposes that exposure of dentine
to an external stimulus causes fluid movement within dentinal tubules
[5]. If these tubules are patent from the pulp to the oral environment
[1], the dentinal shift activates nerve terminals near the tubule base,
eliciting a pain response [6]. This theory has led to development of two
approaches to DH management: physical occlusion of exposed ends of
dentinal tubules, which reduces fluid shift and subsequent nociceptor
activation, or use of desensitizing agents such as potassium nitrate,
which are believed to reduce intradental nerve excitability [7].
Tubule-occluding agents form chemical precipitates on the dentine
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surface and within dentinal tubules. Calcium sodium phosphosilicate
(CSPS; Novamin®, GSK Consumer Healthcare [GSKCH], Weybridge, UK)
is a particulate, bioactive glass material that degrades in the aqueous
oral environment to release calcium and phosphate ions, leading to
formation of hydroxycarbonate apatite on the dentine surface [8–11].
This process creates a physical barrier that mitigates the impact of ex-
ternal stimuli on fluid movement within dentinal tubules [8,9,12–14].
Clinical studies have shown that incorporation of 5% w/w CSPS into
toothpastes is efficacious for DH relief when used over a number of days
or weeks [15–20]. Additionally, studies have demonstrated DH relief
following a single treatment with an occlusive toothpaste when applied
to affected teeth by dabbing or focused brushing prior to whole mouth
brushing [21–28].
Incorporation of CSPS into a dissolvable strip may be a pragmatic
and effective method of exposing a sensitive tooth to sufficient active
ingredient to allow hydroxycarbonate apatite to form on the surface of
exposed dentine. In-vitro data showed that CSPS delivered from a hy-
droxypropyl cellulose (HPC) polymer strip led to dentine occlusion,
apatite formation and a reduction in dentine permeability (Unpublished
results).
The primary objective of this study was to evaluate immediate DH
relief with use of an experimental dissolvable strip containing 15% w/w
CSPS compared with no treatment, assessed using an evaporative (air)
stimulus and the Schiff Sensitivity Scale [29] at 10 min after applica-
tion. The ‘No treatment’ group did not receive any treatment so any
effects cannot be reliably attributed to the specific inclusion of CSPS,
rather than the vehicle strip; however, the main purpose of this proof-
of-principle study, which was the first to investigate the delivery of
CSPS via such a strip, was to determine overall efficacy and safety of the
experimental strip.
Secondary objectives were to assess DH efficacy as above at 2 and
4 h after application, by evaporative (air) stimulus and a numeric rating
scale (NRS) at 10 min, 2 h and 4 h after application, and by a tactile
stimulus (Yeaple probe) at the same time points. Other objectives were
to assess ease of strip use, strip dissolution time, and the sensory ex-
perience of study participants when using the strip.
Materials and methods
This was a single-center, randomized, two-arm, examiner-blind,
parallel-group, proof-of-principle study in healthy participants with
self-reported and clinically diagnosed DH and at least two sensitive
teeth. The study was conducted at a US-based clinical research facility
in accordance with the Declaration of Helsinki, the International
Conference on Harmonization of Technical Requirements for
Registration of Pharmaceuticals for Human Use and local laws and
regulations. The protocol was approved by the US Investigational
Review Board, Inc (IRB no. U.S.IRB2016SRG/06); the study was re-
gistered at clinicaltrials.gov (NCT02937623). Anonymized individual
participant data and study documents can be requested for further re-
search from www.clinicalstudydatarequest.com.
Participants
Study participants were required to be aged 18–65 y with ≥20
natural teeth, in good general health, with a self-reported history of DH
of between 0.5–10 y. Participants were recruited from the existing
study site database. At screening, eligible participants had at least two
accessible non-adjacent teeth in different quadrants with signs of ero-
sion, abrasion, or facial/cervical gingival recession (EAR) as assessed by
a visual examination; a modified gingival index (MGI) score of 0 [30],
clinical mobility of ≤1 [31]; and a positive response to a qualifying
evaporative (air) assessment. At baseline, eligible participants had a
minimum of two accessible, non-adjacent teeth with signs of DH, as
determined by a qualifying tactile stimulus threshold of≤20 g [32] and
a Schiff sensitivity score of ≥2 [29] (see ‘Clinical procedures’ for
details).
Participants were excluded if they had a chronic debilitating dis-
ease; had any condition/medication causing xerostomia; received daily
doses of treatments that could interfere with pain perception; had
current/recent (2 weeks) use of antibiotics; were pregnant or breast-
feeding; had known/suspected allergy/intolerance to study materials/
ingredients; had tongue/lip piercings; or had undergone dental pro-
phylaxis within 4 weeks, desensitizing treatment or tooth bleaching
within 8 weeks, scaling or root planing within 3 months of screening;
had gross periodontal disease or treatment of periodontal disease
within 12 months; or had participated in another clinical study or re-
ceived an investigational drug within 30 d of screening.
Specific dentition exclusions for test teeth included: evidence of
current/recent caries, or reported treatment of decay within 12 months
of screening; exposed dentine but with deep, defective, or facial re-
storations; teeth used as abutments for dentures; dental implants; full
crowns or veneers; orthodontic bands; cracked enamel; sensitive teeth
with etiologies other than EAR; or sensitive teeth not expected to re-
spond to an over-the-counter DH toothpaste.
Clinical procedures
At the screening visit, participants gave written informed consent to
participate, and their demographic characteristics, medical history and
concomitant medications were recorded. Participants underwent oral
soft tissue (OST) and oral hard tissue examinations and assessments to
determine eligible teeth. Dentition was assessed sequentially for evi-
dence of EAR, gingival health status (MGI score = 0), tooth mobility
≤1, and sensitivity to an air-jet stimulus (where a “yes” response in-
dicated sensitivity). Eligible participants were supplied with a standard
fluoride toothpaste (Crest® Cavity Protection, 0.15% w/v fluoride as
sodium fluoride ion; Procter & Gamble, Cincinnati, OH, USA) and a
toothbrush (Oral-B Sensi-soft® manual tooth brush; Procter & Gamble),
which they used twice daily for a 1 or 2 week acclimatization period
(depending on scheduling of the baseline visit) between screening and
baseline visits.
Participants could not use any oral care products indicated for DH
relief within 8 weeks of screening until study completion or chew gum
throughout the study. Before visits, participants refrained from all oral
hygiene procedures or from taking analgesics for at least 8 h, from
eating and drinking for at least 4 h, and from excessive alcohol con-
sumption for 24 h. Small sips of water were permitted within 4 h of
visits (but not within 1 h). Participants were requested to delay any
non-emergency elective dental treatment or prophylaxis until after
study completion. During the study, participants could only use the oral
care products provided.
At the baseline visit, prior to treatment, ongoing eligibility was as-
sessed; any adverse events (AEs), incidents and changes to concomitant
medications were recorded, and acclimatization toothpaste adherence
was confirmed. An OST examination was completed by the first ex-
aminer (non-index reading examiner). Sensitivity of the identified
clinically eligible teeth was then evaluated by the second examiner
(index scoring examiner) by the participant’s response to a tactile sti-
mulus. Tactile sensitivity was assessed using an electronic constant-
pressure force-sensing (Yeaple) probe [32] that allowed application of a
known force to the dentine surface, starting at 10 g and rising in in-
crements of 10 g. The gram setting that elicited two consecutive “yes”
responses from the participant (where “yes” indicated that the stimulus
caused pain/discomfort) was recorded as the tactile threshold. At
baseline, the maximum force used was 20 g; after treatment, it was
80 g. Pain at 80 g was recorded as such; no pain at 80 g was recorded
as> 80 g.
As recommended, two independent stimulus-based efficacy mea-
sures were used to assess DH [33]. Following a 5-min break to allow for
tooth recovery, teeth with a tactile threshold≤20 g were evaluated for
sensitivity to an evaporative (air) stimulus. The examiner directed a
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maximum 1 s air blast from a distance of 1 cm onto the exposed dentine
surface of each test tooth in turn, having first isolated the surface to
prevent adjacent teeth or surrounding soft tissue being exposed to the
stimulus. The examiner assessed the participant’s response to the sti-
mulus using the 4-point Schiff Sensitivity Scale (from 0 = participant
does not respond to air stimulus to 3 = participant responds to sti-
mulus, considers stimulus to be painful, and requests discontinuation of
the stimulus) [28]. Participants also rated the intensity of their response
to the evaporative (air) stimulus using a 10-point NRS (from 1 = ‘no
pain’ to 10 = ‘intense pain’). From those that met the qualifying sen-
sitivity assessments, the investigator selected two non-adjacent teeth to
be evaluated for the remainder of the study.
Study groups
Eligible participants were randomized (1:1) according to a schedule
provided by the Biostatistics Department of the study sponsor.
Randomization was stratified by maximum baseline Schiff sensitivity
score (either 2 or 3) of the two selected test teeth. Participants were
randomised to either receive the test product applied to the chosen
teeth or to receive no treatment. The test product was an experimental
dissolvable HPC polymer strip containing 15% w/w CSPS, which was
evenly-distributed throughout the strip. One strip was applied to the
facial surface of each of the two selected test teeth by a member of the
site staff not involved in collection of efficacy data and OST measures.
The strip was positioned using light finger pressure, targeting the center
of the strip with the center of the tooth. All areas of exposed dentine
were covered, especially at the gingival margin. Any excess film was
folded over the tooth’s occlusal surface.
The dental examiner (for the sensitivity assessments), study statis-
ticians and other employees of the study sponsor who could have in-
fluenced study outcomes were blinded to treatment allocation.
Participants were instructed not to disclose to the examiners or other
study participants whether or not the Test strip had been applied.
Following strip application, the staff member completed a three-
item questionnaire (see Supplemental information for full details): 1)
How easy was the strip to apply? (from 1 = not easy at all to 5 =
extremely easy); 2) How long did it take for the strip to dissolve on the
facial tooth surface? (from 1 = up to 5 min to 3 = not dissolved at
10 min); and 3) After 10 min following strip application was any visible
residue observed? (from 1 = no residue to 4 = residue present on both
facial surface and interproximally). Strip dissolution and the presence
of any residue was monitored by the staff member who applied it by
carefully mobilizing the adjacent labial/buccal mucosa at 5 and 10 min
following application using a dental mirror and lighting as appropriate
and taking care not to potentially disrupt strip dissolution. If any visible
residue was present at 10 min, the staff member removed it using a
cotton bud or a blunt/ball-ended probe for the interproximal surfaces.
Care was taken not to instrument the tooth surface.
Immediately following application, participants in the Test strip
group completed a 2-item questionnaire (see Supplemental information
for full details): 1) Please describe how the strip felt on your tooth
before it dissolved (free text answer); 2) How would you rate the
strength of the taste? (from 1 = slightly too weak to 3 = slightly too
strong).
At 10 (+5) min, 2 h (± 10 min) and 4 h (± 10 min) following
treatment (or from a designated study start time for those not receiving
treatment), the sensitivity of the two test teeth was evaluated by tactile
stimulus response and evaporative (air) stimulus response, performed
at least 5 min apart. Another examiner was assigned to the OST eva-
luation to assess gingival irritation associated with the strip or strip
residue prior to (and following) the second examiner conducting sen-
sitivity evaluations.
At 4 h (± 10 min), all participants underwent an OST examination;
those in the Test strip group completed a 5-item questionnaire: 1) How
comfortable was the strip to wear (from 1 = not at all comfortable to 5
= extremely comfortable); 2) How much residue of the strip do you feel
was left on your teeth? (from 1 = a lot of residue to 4 = no residue at
all); 3/4) What are the things you liked/disliked about the usage ex-
perience with this product (free text answers); 5) How much did you
like the overall usage experience? (from 1 = dislike extremely to 7 =
like extremely).
Safety
AEs were recorded from first use of acclimatization toothpaste until
5 d after last administration of the Test strip. OST abnormalities were
included as AEs if they appeared or worsened after administration of
the acclimatization toothpaste. AEs were regarded as treatment emer-
gent if they occurred on or after strip application (or randomization for
no treatment group). Clinical judgement was exercised by the in-
vestigator to assess the relationship between the Test strip and any AE
occurrence, with intensity graded as mild, moderate or severe. The
safety population included all randomized participants who received
the study treatment.
Statistical analysis
Sufficient participants were screened so that at least 118 (approxi-
mately 59 per group) could be randomized to the study, ensuring that
approximately 110 evaluable participants completed the study. This
would permit a mean difference of 0.35 (standard deviation [SD]
0.6464) in change from baseline Schiff sensitivity score after 10 min to
be detected with 80% power, based on results from previous studies
(Unpublished results). Statistical analyses were conducted under the
null hypothesis of no difference between treatments versus the alternate
hypothesis of a difference between treatments. All tests were 2-sided
with a significance level of 5%. Analyses were performed using
Statistical Analysis System version 9.2 (SAS Institute Inc., Carey, NC,
USA). The efficacy analysis was performed on a modified intent-to-treat
(ITT) population, defined as all participants who received the study
treatment and had at least one post-baseline efficacy measurement. The
per protocol (PP) population was defined as all participants in the ITT
population who had at least one assessment of efficacy considered
unaffected by protocol violations.
Change from baseline in Schiff sensitivity score was analyzed using
analysis of covariance (ANCOVA) with treatment as a factor and
baseline Schiff sensitivity score as a covariate. Change from baseline in
tactile threshold and NRS scores were analyzed using ANCOVA with
treatment and baseline Schiff sensitivity score stratification as factors
and corresponding baseline variable as a covariate. Staff and partici-
pant questionnaires were summarized in terms of the number and
percentage of participants.
Results
The first participant was enrolled in November 2016; the final
participant completed the study in December 2016. Of the 135 in-
dividuals screened, 120 were randomized to treatment and all partici-
pants completed the study (Fig. 1). Participants were aged between 20
and 63 y (mean 38.2; SD 11.52), and the majority were female (65.8%).
Study groups were well balanced at baseline (Table 1). Twenty-four
participants had an acclimatization period of 1 week and 96 partici-
pants had an acclimatization period of 2 weeks. Mean baseline Schiff
sensitivity scores were similar: 2.52 (SD 0.375) and 2.51 (0.429), re-
spectively.
Schiff sensitivity scores
At 10 min after Test strip application or no treatment, the mean
changes in Schiff sensitivity score from baseline (primary endpoint) was
statistically significant in the Test strip group (−0.46; p < 0.0001) but
not the No treatment group (−0.02) (Fig. 2a; Table 2). The between-
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treatment group mean adjusted difference was statistically significant
in favor of the Test strip (p < 0.0001). Significant adjusted mean
differences between treatments were also observed in favor of the Test
strip at 2 and 4 h after application (p < 0.0001 at both time points)
with treatment difference increasing over time (Table 2).
Tactile threshold
At the 10 min, 2 h and 4 h time points, the mean changes in tactile
threshold values from baseline were statistically significant in the Test
strip group (p < 0.0001 at each time point) but not in the No treat-
ment group (Fig. 2b; Table 2). The between-treatment group mean
adjusted difference was statistically significant in favor of the Test strip
at each evaluation point (p < 0.0001 at all time points) (Table 2).
NRS
At the 10 min, 2 h and 4 h time points, the mean changes in NRS
from baseline were statistically significant in the Test strip group
(p < 0.0001 at each time point) (Fig. 2c; Table 2). A statistical dif-
ference compared with baseline was seen at 2 h only in the No treat-
ment group (p = 0.0124). The between-treatment group mean adjusted
difference was statistically significant in favor of the Test strip at each
time point (p < 0.0001 at all time points) (Table 2).
Staff and participant questionnaires
A summary of staff questionnaire responses made immediately fol-
lowing Test strip application is presented in Table 3. Test strips were
most frequently reported as “slightly easy to apply” (68.3%). Most
strips had dissolved within 10 min (95.0%).
Responses to the participant questionnaires are presented in
Table 4. Most participants (85%) reported the strength of taste as “just
right”. Strips were most frequently reported as “very comfortable”
(38.3%) or “somewhat comfortable” (33.3%) with no residue (45.0%)
or a slight amount of residue (33.3%) left on the teeth at 10 min. Sixty
percent of participants rated the overall strip usage experience as “like
moderately/extremely”.
Safety
Three AEs (cough, traumatic ulcer and chronic cheek biting) were
reported by three participants; none of these AEs were treatment
emergent or treatment-related. All reported AEs were mild in nature
and resolved without action. There were no serious AEs or incidents
and no participants were withdrawn/withdrew because of an AE.
Discussion
This proof-of-principle clinical study was the first to investigate the
delivery of CSPS via a dissolvable strip. There were statistically sig-
nificantly greater reductions in DH, as elicited by evaporative (air) and
tactile stimuli, in participants using the dissolvable strip containing
CSPS compared with those not receiving treatment. Participant-elicited
pain intensity ratings in response to the evaporative (air) stimulus,
measured using an NRS, were also less in the Test strip group. There is
no consensus as to what level of response is clinically significant.
However, according to criteria set out by Orchardson et al. [34], a
treatment can be deemed clinically effective if there is at least “a 33%
reduction in mean baseline sensitivity.” In this study, the difference
from baseline for Schiff scores with the Test strip was 18% at 10 min,
31% at 2 h and 41% at 4 h, indicating that this treatment may be
clinically effective. Further studies (posited below) would be needed to
Fig. 1. Study flow.
Table 1
Participant demographics and baseline characteristics.
Test strip
(N = 60)
No treatment
(N = 60)
Gender, n (%) Female 40 (66.7) 39 (65.0)
Male 20 (33.3) 21 (35.0)
Race, n (%) White 34 (56.7) 26 (43.3)
Black/African-American 15 (25.0) 25 (41.7)
Asian 5 (8.3) 0
Other/Multiple 6 (10.0) 9 (15.0)
Mean age (SD), range (years) 37.6 (11.75)
20–59
38.8 (11.36) 20–63
Maximum baseline Schiff
sensitivity score, n (%)
2.0 20 (33.3) 20 (33.3)
3.0 40 (66.7) 40 (66.7)
Fig. 2. A) Schiff sensitivity score; B) Tactile threshold; C) Numeric rating scale
(NRS) by treatment and time (mean ± standard error; Intent-to-treat popula-
tion).
Data are offset for clarity. Lower Schiff sensitivity and NRS scores are favorable;
higher tactile thresholds are favorable. BL, baseline.
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confirm this.
Differences were seen as early as 10 min after application and ap-
peared to increase over the 4 h test period. This is an important aspect
of a DH treatment as people experiencing DH report the detrimental
impact that symptoms can have on quality of life aspects including
eating, drinking, talking and social interactions [35]. An easy-to-apply
strip that delivers rapid relief from DH to affected teeth only would be
convenient for individuals with DH to use inside and outside the home
both for symptom relief and in anticipation of a DH-stimulating activity
such as eating.
In-vitro testing of CSPS on HPC polymer strips demonstrated dentine
occlusion and apatite formation in a dose-response manner with in-
creasing CSPS content (Unpublished results). The most effective for-
mulation in terms of apatite formation (important for long-term sub-
stantively of the occluding layer) was 15% w/w CSPS. A reduction in
dentine permeability (fluid flow) was recorded for different CSPS con-
centrations; however, this included reduction with the polymer strip
without CSPS.
It is important to note that there are limitations to this current
study. While it met its primary and secondary endpoints, the ‘No
treatment’ group did not receive a non-CSPS vehicle control strip; it is
therefore not possible to ascertain whether DH relief was due to the
action of CSPS or to the strip itself. However, this was a proof-of-
principle, first-in-human study whose main purpose was to determine
overall efficacy and safety profile of this novel CSPS treatment delivery
option. Further clinical studies would need to include a placebo control
strip and different concentrations of active ingredients to establish the
role of CSPS in this novel format.
No treatment-emergent AEs were reported with the Test strip and
there were no observations of abnormalities that appeared or worsened
after initial assessment. As such, data obtained from this study provide
an important insight into the overall safety profile of CSPS delivered
within the vehicle strip. This will form the basis for additional clinical
testing.
In terms of usability, the study staff who applied the strips to the
participants generally found them moderately/slightly easy to apply,
with most strips taking between 5 and 10 min to dissolve. Only three of
the 60 participants receiving the Test strip felt that there was a lot of
residue left on their teeth, and most participants liked the overall usage
experience. This suggests that such a strip would be an acceptable op-
tion for the rapid treatment of DH symptoms.
In conclusion, the experimental dissolvable strip containing 15% w/
w CSPS was well tolerated and demonstrated statistically significant,
Table 2
Summary Statistics of evaporate (Air) sensitivity (Schiff Sensitivity Score and Numeric Rating Scale) and tactile threshold (g) scores plus adjusted mean change vs
baseline in efficacy parameters at each time point (Intent-to-treat population). Primary/secondary analyses.
Test strip (n = 60) No treatment (n = 60) Test strip (n = 60) No treatment (n = 60)
Mean (standard error) (% change from baseline) Adjusted mean change from baseline (95% CI) p-value Difference (95% CI) p-value
Schiff sensitivity scorea
BL 2.51 (0.054) 2.52 (0.054)
10 min 2.05 (0.074) (18.3%) 2.50 (0.057) (0.8%) −0.46 (−0.563, −0.356) 0.0001 −0.02 (−0.119, 0.088) 0.7664 −0.44 (−0.591, −0.297) 0.0001
2 h 1.73 (0.084) (31.1%) 2.43 (0.061) (3.6%) −0.78 (−0.905, −0.648) 0.0001 −0.08 (−0.210, 0.046) 0.2082 −0.69 (−0.876, −0.513) 0.0001
4 h 1.48 (0.081) (41.0%) 2.40 (0.065) (4.8%) −1.03 (−1.161, −0.893) 0.0001 −0.11 (−0.249, 0.019) 0.0926 −0.91 (−1.102, −0.723) 0.0001
Tactile threshold (g)b
BL 10.00 (0) 10.00 (0)
10 min 18.92 (1.366) (88.2%) 10.50 (0.308) (5%) 8.92 (6.998, 10.835) 0.0001 0.50 (−1.419, 2.419) 0.6068 8.42 (5.703, 11.130) 0.0001
2 h 26.50 (2.120) (165.5%) 10.75 (0.310) (7.5%) 16.50 (13.550, 19.450) 0.0001 0.75 (−2.200, 3.700) 0.6155 15.75 (11.578, 19.922) 0.0001
4 h 34.00 (2.673) (240.0%) 10.92 (0.303) (9.2%) 24.00 (20.310, 27.690) 0.0001 0.92 (−2.774, 4.607) 0.6237 23.08 (17.864, 28.302) 0.0001
Numeric Rating Scalea
BL 6.38 (0.220) 6.35 (0.207)
10 min 4.94 (0.232) (22.6%) 6.24 (0.226) (1.7%) −1.44 (−1.753, −1.122) 0.0001 −0.11 (−0.428, 0.203) 0.4819 −1.33 (−1.771, −0.880) 0.0001
2 h 4.47 (0.250) (30.0%) 5.88 (0.236) (7.4%) −1.91 (−2.280, −1.545) 0.0001 −0.47 (−0.838, −0.104) 0.0124 −1.44 (−1.961, −0.922) 0.0001
4 h 3.89 (0.233) (39.0%) 6.03 (0.230) (5.0%) −2.49 (−2.845, −2.126) 0.0001 −0.33 (−0.691, 0.029) 0.0710 −2.15 (−2.663, −1.646) 0.0001
P-values indicating statistically significant within and between-treatment comparisons are highlighted in bold; BL: Baseline.
a Difference is Test strip minus No treatment such that a negative difference favors the Test strip.
b Difference is Test strip minus No treatment such that a positive difference favors the Test strip.
Table 3
Staff and participant questionnaire responses to Test strip application (n = 60)
(Intent-to-treat population; only in group receiving test strip).
Question Response n (%)
How easy was the strip to apply? Not easy at all 0
Slightly easy 41 (68.33)
Moderately easy 18 (30.00)
Very easy 1 (1.67)
Extremely easy 0
How long did it take for strip to
dissolve on facial tooth surface?
Up to 5 min 0
Up to 10 min 57 (95.00)
Not dissolved at 10 min 3 (5.00)
10 min following application, was any
visible residue observed?
No residue 25 (41.67)
Facial surface only 0
Interproximally only 20 (33.33)
Facial surface and
interproximally
15 (25.00)
Table 4
Participant questionnaire responses for Test strip (n = 60) (Intent-to-treat po-
pulation; only in group receiving test strip).
Question Response n (%)
How would you rate the strength of the
taste? (10 min)
Slightly too weak 6 (10.00)
Just right 51 (85.00)
Slightly too strong 3 (5.00)
How comfortable was the strip to wear?
(4 h)
Not at all comfortable 1 (1.67)
Not very comfortable 7 (11.67)
Somewhat comfortable 20 (33.33)
Very comfortable 23 (38.33)
Extremely comfortable 9 (15.00)
How much residue do you feel was left on
your teeth? (4 h)
A lot of residue 3 (5.00)
A moderate amount of
residue
10 (16.67)
A slight amount of
residue
20 (33.33)
No residue at all 27 (45.00)
How much did you like the overall usage
experience? (4 h)
Dislike extremely 1 (1.67)
Dislike moderately 1 (1.67)
Dislike slightly 2 (3.33)
Neither liked nor
disliked
11 (18.33)
Like slightly 9 (15.00)
Like moderately 24 (40.00)
Like extremely 12 (20.00)
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greater reductions in DH after 10 min, 2 h, and 4 h following a single-
use compared with no treatment. This new technology may provide a
novel treatment option for rapid relief from the symptoms of DH.
Further studies are required to fully understand the efficacy of this
product.
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